Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2006

Open Access 01-12-2006 | Research

Brachytherapy of stage II mobile tongue carcinoma. Prediction of local control and QOL

Authors: Sayako Oota, Hitoshi Shibuya, Ryo-ichi Yoshimura, Hiroshi Watanabe, Masahiko Miura

Published in: Radiation Oncology | Issue 1/2006

Login to get access

Abstract

Background

There is no consensus as to the prognostic model for brachytherapy of tongue carcinoma. This study was designed to evaluate the prognostic factors for local control based on a large population under a unified treatment policy.

Results

Between 1970 and 1998, 433 patients with stage II tongue squamous cell carcinoma were treated by low-dose-rate brachytherapy. This series included 277 patients treated with a linear source with a minimum follow-up of 3 years. A spacer was introduced in 1987. The primary local control rates were 85.6%.

Conclusion

In the multivariate analysis, an invasive growth pattern was a significant factor for local recurrence. The disease-related survival was influenced by old age and an invasive growth pattern. A spacer lowered mandibular bone complications. The growth pattern was the most important factor for recurrence. Brachytherapy was associated with a high cure rate and the use of spacers brought about good quality of life (QOL).
Appendix
Available only for authorised users
Literature
1.
WHO collaborating centre for oral precancerous lesions: Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol 1978, 46: 518-539.CrossRef
2.
Waar van der I, Schepman KP, Meij van der EH, et al.: Oral leukoplakia: a clinicopathological review. Oral Oncology 1997,33(5):291-307. 10.1016/S1368-8375(97)00002-XCrossRef
3.
Shibuya H, Hoshina M, Takeda M, et al.: Brachytherapy for stage I & II oral tongue cancer: an analysis of past cases focusing on control and complications. Int J Radiat Oncol Biol Phys 1993,26(1):51-58.CrossRefPubMed
4.
Miura M, Takeda M, Sasaki T, et al.: Factors affecting mandibular complications in low dose rate brachytherapy for oral tongue carcinoma with special reference to spacer. Int J Radiat Oncol Biol Phys 1998,41(4):763-770. 10.1016/S0360-3016(98)00118-7CrossRefPubMed
5.
Delclos L, Lindberg RD, Fletcher GH: Squamous cell carcinoma of the oral tongue and floor of mouth: Evaluation of interstitial radium therapy. Am J Roentgenol 1976,126(2):223-228.CrossRef
6.
Lefebvre JL, Coche-Dequeant B, Castelain B, et al.: Interstitial brachytherapy and early tongue squamous cell carcinoma management. Head Neck 1990, 12: 232-236.CrossRefPubMed
7.
Leung TW, Wong VY, Kwan KH, et al.: High dose rate brachytherapy for early stage oral tongue cancer. Head Neck 2002,24(3):274-81. 10.1002/hed.10021CrossRefPubMed
8.
Mazeron JJ, Crook JM, Marinello G, et al.: Prognostic factors of local outcome for T1, T2 carcinomas treated by iridium 192 implantation. Int J Radiat Oncol Biol Phys 1990, 19: 281-285.CrossRefPubMed
9.
Shibuya H, Amagasa T, Seto K, et al.: Leukoplakia-associated multiple carcinomas in patients with tongue carcinoma. Cancer 1986, 57: 843-846. PublisherFullTex​t 10.1002/1097-0142(19860215)57:4<843::AID-CNCR2820570426>3.0.CO;2-WCrossRefPubMed
10.
Bourgier C, Coche-Dequeant B, Fournier C, et al.: Exclusive low-dose rate brachytherapy in 279 patients with T2N0 mobile tongue carcinoma. Int J Radiat Oncol Biol Phys 2005, 63: 434-40. 10.1016/j.ijrobp.2005.02.014CrossRefPubMed
11.
Pourel N, Peiffert D, Lartigau E, et al.: Quality of life in long-term survivors of oropharynx carcinoma. Int J Radiat Oncol Biol Phys 2002, 54: 742-51. 10.1016/S0360-3016(02)02959-0CrossRefPubMed
12.
Wendt CD, Peters LJ, Delclos L, et al.: Primary radiotherapy in the treatment of stage I and II oral tongue cancers: importance of the proportion of therapy delivered with interstitial therapy. Int J Radiat Oncol Biol Phys 1990,18(6):1287-92.CrossRefPubMed
13.
Yuen APW, Lam KY, Lam LK, et al.: Prognostic factors of clinically stage I and II oral tongue carcinoma-a comparative study of stage, thickness, shape, growth pattern, invasive front malignancy grading, Martinez-Gimeno score, and pathologic features. Head Neck 2002, 24: 513-520. 10.1002/hed.10094CrossRefPubMed
14.
Paterson R: The treatment of malignant disease by radiotherapy. Edited by: Paterson R, Stewart JG. London: Edward Arnold Publishers; 1963:204-234.
15.
Al-Rajhi N, Khafaga Y, El-Husseiny J, et al.: Early stage carcinoma of oral tongue: prognostic factors for local control and survival. Oral Oncology 2000, 36: 508-514. 10.1016/S1368-8375(00)00042-7CrossRefPubMed
16.
Siegelmann-Danieli N, Hanlon A, Ridge JA, et al.: Oral tongue cancer in patients less than 45 years old: institutional experience and comparison with older patients. J Clin Oncol 1998, 16: 745-753.PubMed
17.
Yoshida K, Koizumi M, Inoue T, et al.: Radiotherapy of early tongue cancer in patients less than 40 years old. Int J Radiat Oncol Biol Phys 1999, 45(2);: 367-371. 10.1016/S0360-3016(99)00164-9CrossRefPubMed
18.
Sudbø J, Bankfalvi A, Bryne M, et al.: Prognostic value of graph theory-based tissue architecture analysis in carcinomas of the tongue. Lab Invest 2000,80(12):1881-1889.CrossRefPubMed
19.
Hoşai AŞ, Ünal ÖF, Ayhan A: Possible prognostic value of histopathologic parameters in patients with carcinoma of the oral tongue. Eur Arc Otorhinolaryngol 1998, 255: 216-219. 10.1007/s004050050046CrossRef
20.
Nyman J, Mercke C, Lindström J: Prognostic factors for local control and survival of cancer of the oral tongue A retrospective analysis of 230 cases in Western Sweden. Acta oncologica 1993,32(6):667-673.CrossRefPubMed
21.
Nakagawa T, Shibuya H, Yoshimura R, et al.: Neck node metastasis after successful brachytherapy for early stage tongue carcinoma. Radiother Oncol 2003,68(2):129-35. 10.1016/S0167-8140(03)00187-7CrossRefPubMed
22.
Silverman S, Gorsky M, Lozada F: Oral leukoplakia and malignant transformation. Cancer 1984, 53: 563-568. PublisherFullTex​t 10.1002/1097-0142(19840201)53:3<563::AID-CNCR2820530332>3.0.CO;2-FCrossRefPubMed
23.
Pernot M, Malissard L, Hoffstetter S, et al.: The study of tumoral, radiobiological, and general health factors that influence results and complications in a seriese of 448 oral tongue carcinomas treated exclusively by irradiation. Int J Radiat Oncol Biol Phys 1994, 29: 673-9.CrossRefPubMed
24.
Kolotas C, Baltas D, Zamboglou N, et al.: CT-Based interstitial HDR brachytherapy. Strahlenther Onkol 1999, 175: 419-27. 10.1007/s000660050031CrossRefPubMed
25.
Umeda M, Komatsubara H, Nishimatsu N, et al.: High-dose rate interstitial brachytherapy for stage I-II tongue cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000, 90: 667-70.CrossRefPubMed
Metadata
Title
Brachytherapy of stage II mobile tongue carcinoma. Prediction of local control and QOL
Authors
Sayako Oota
Hitoshi Shibuya
Ryo-ichi Yoshimura
Hiroshi Watanabe
Masahiko Miura
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2006
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-1-21

Other articles of this Issue 1/2006

Radiation Oncology 1/2006 Go to the issue

Review

Radiation therapy planning with photons and protons for early and advanced breast cancer: an overview

Research

A prospective study of differences in duodenum compared to remaining small bowel motion between radiation treatments: Implications for radiation dose escalation in carcinoma of the pancreas

Short report

Concurrent capecitabine and upper abdominal radiation therapy is well tolerated

Review

Radiosensitizers in cervical cancer. Cisplatin and beyond

Research

Early observed transient prostate-specific antigen elevations on a pilot study of external beam radiation therapy and fractionated MRI guided High Dose Rate brachytherapy boost

Research

Dosimetric comparison of intensity-modulated, conformal, and four-field pelvic radiotherapy boost plans for gynecologic cancer: a retrospective planning study